Search results
Results from the WOW.Com Content Network
Zavegepant is a calcitonin gene-related peptide receptor antagonist. [1] It is sprayed into the nose. [1] It is sold by Pfizer. [1] The most common adverse reactions include taste disorders, nausea, nasal discomfort, and vomiting. [1] Zavegepant was approved for medical use in the United States in March 2023. [1] [2] [3] [4]
Intranasal calcitonin, calcitonin-salmon, is used to treat hypercalcaemia arising out of malignancy, Paget's disease of bone, post menopausal and steroid induced osteoporosis, phantom limb pain and other metabolic bone abnormalities, available as Rockbone, Fortical and Miacalcin Nasal Spray.
In addition to the injectable and nasal spray dosage forms of the salmon calcitonin, noninvasive oral formulations of the peptide are currently under clinical development. The short-half-life of this peptide in serum triggered several attempts to enhance plasma concentrations.
Calcitonin gene-related peptide (CGRP) receptor antagonists, commonly known as gepants, are a class of drugs that act as antagonists of the calcitonin gene-related peptide receptor (CGRPR). [ 1 ] Several monoclonal antibodies that bind to the CGRP receptor or peptide have been approved for prevention of migraine. [ 2 ]
Decongestant nasal sprays are advised for short-term use only, preferably 5 to 7 days at maximum. Some doctors advise to use them 3 days at maximum. A recent clinical trial has shown that a corticosteroid nasal spray may be useful in reversing this condition. [3] Topical nasal decongestants include: Oxymetazoline; Phenylephrine; Xylometazoline
The calcitonin gene-related peptide (CGRP) is a therapeutic target in migraine because of its hypothesized role in mediating trigeminovascular pain transmission and the vasodilatory component of neurogenic inflammation (see "Pathophysiology, clinical manifestations, and diagnosis of migraine in adults", section on 'Role of calcitonin gene ...
Additionally, there is question of the overall efficacy of calcitonin-containing nasal sprays. A phase III trial found no difference between placebo and nasal calcitonin sprays on lumbar bone mineral density in osteoporosis. [34] It did find a significant increase in bone mineral density with oral calcitonin.
Nasal delivery of this gel demonstrated increased drug concentration in the brain. [17] Oxytocin is a hormone which is observed to alleviate anxiety symptoms in people with autism. Intranasal administration indicated efficient transfer of pharmacologically active oxytocin from nasal cavity to brain.